enGene Holdings Inc. announced on October 1, 2025, the appointment of Hussein Sweiti, M.D., MSc, as Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with over 15 years of experience in oncology clinical research and global drug development.
Dr. Sweiti most recently served as Global Medical Head, Oncology Clinical Development at Johnson & Johnson, where he led clinical strategy for their bladder cancer portfolio. He was intimately involved in FDA interactions that culminated in J&J’s recent FDA approval in high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
This appointment is a strategic move as enGene transitions its focus to regulatory filing and commercialization for detalimogene, its lead investigational candidate. Dr. Sweiti's expertise and recent success in the NMIBC space are expected to significantly strengthen enGene's clinical development and regulatory capabilities ahead of its planned BLA submission in the second half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.